Correlation Between SCANDMEDICAL SOLDK-040 and BlueScope Steel

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both SCANDMEDICAL SOLDK-040 and BlueScope Steel at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SCANDMEDICAL SOLDK-040 and BlueScope Steel into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between SCANDMEDICAL SOLDK 040 and BlueScope Steel Limited, you can compare the effects of market volatilities on SCANDMEDICAL SOLDK-040 and BlueScope Steel and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SCANDMEDICAL SOLDK-040 with a short position of BlueScope Steel. Check out your portfolio center. Please also check ongoing floating volatility patterns of SCANDMEDICAL SOLDK-040 and BlueScope Steel.

Diversification Opportunities for SCANDMEDICAL SOLDK-040 and BlueScope Steel

-0.15
  Correlation Coefficient

Good diversification

The 3 months correlation between SCANDMEDICAL and BlueScope is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding SCANDMEDICAL SOLDK 040 and BlueScope Steel Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BlueScope Steel and SCANDMEDICAL SOLDK-040 is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SCANDMEDICAL SOLDK 040 are associated (or correlated) with BlueScope Steel. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BlueScope Steel has no effect on the direction of SCANDMEDICAL SOLDK-040 i.e., SCANDMEDICAL SOLDK-040 and BlueScope Steel go up and down completely randomly.

Pair Corralation between SCANDMEDICAL SOLDK-040 and BlueScope Steel

Assuming the 90 days horizon SCANDMEDICAL SOLDK 040 is expected to under-perform the BlueScope Steel. In addition to that, SCANDMEDICAL SOLDK-040 is 1.2 times more volatile than BlueScope Steel Limited. It trades about 0.0 of its total potential returns per unit of risk. BlueScope Steel Limited is currently generating about 0.07 per unit of volatility. If you would invest  1,190  in BlueScope Steel Limited on September 10, 2024 and sell it today you would earn a total of  110.00  from holding BlueScope Steel Limited or generate 9.24% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

SCANDMEDICAL SOLDK 040  vs.  BlueScope Steel Limited

 Performance 
       Timeline  
SCANDMEDICAL SOLDK 040 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days SCANDMEDICAL SOLDK 040 has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, SCANDMEDICAL SOLDK-040 is not utilizing all of its potentials. The newest stock price disturbance, may contribute to mid-run losses for the stockholders.
BlueScope Steel 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in BlueScope Steel Limited are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, BlueScope Steel may actually be approaching a critical reversion point that can send shares even higher in January 2025.

SCANDMEDICAL SOLDK-040 and BlueScope Steel Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with SCANDMEDICAL SOLDK-040 and BlueScope Steel

The main advantage of trading using opposite SCANDMEDICAL SOLDK-040 and BlueScope Steel positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SCANDMEDICAL SOLDK-040 position performs unexpectedly, BlueScope Steel can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BlueScope Steel will offset losses from the drop in BlueScope Steel's long position.
The idea behind SCANDMEDICAL SOLDK 040 and BlueScope Steel Limited pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance